<DOC>
	<DOCNO>NCT02531165</DOCNO>
	<brief_summary>Prospective , randomize , open-label , single-center , investigator-initiated trial , include patient ST-segment elevation myocardial infarction ( STEMI ) undergo primary percutaneous coronary intervention ( PPCI ) within 12 hour symptom 's onset . The study aim compare platelet inhibition ( pharmacodynamics pharmacokinetics ) pre-hospital Ticagrelor patient STEMI accord two different analgesia protocol use Fentanyl Morphine .</brief_summary>
	<brief_title>Platelet Inhibition After Pre-hospital Ticagrelor Using Fentanyl Compared Morphine Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention</brief_title>
	<detailed_description>Consecutive patient acute STEMI within 12 hour symptom ' onset candidate PPCI screen inclusion study . Eligible patient require analgesia relief acute chest pain , define Visual Analogue Scale â‰¥3 , randomize 1:1 ratio one two treatment arm receive analgesia either Morphine Fentanyl follow administration pre-hospital load dose Ticagrelor . Randomized patient undergo primary PCI manage accord current guideline European Society Cardiology . Blood sample ( 10 ml ) collect 0 , 1 , 2 , 4 , 6 , 12 24 hour load dose Ticagrelor ass platelet inhibition use VerifyNow P2Y12 function Vasodilator-Stimulated-phosphoprotein Phosphorylation ( VASP ) assay , plasma concentration Ticagrelor active metabolite ( AR-C124910XX ) use validate liquid chromatography/mass spectrometry detection method procoagulant action platelet .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Age &gt; 18yearold STEMI within 12 hour symptom ' onset eligible primary PCI stent implantation . Patient able give write informed consent . Contraindication , intolerance hypersensitivity Ticagrelor , excipients Contraindication , intolerance hypersensitivity Morphine , Fentanyl , excipients Active bleed bleed diathesis History intracranial haemorrhage Chronic oral anticoagulation treatment Previous antiplatelet treatment Contraindications antiplatelet therapy Severe renal insufficiency ( creatinine clearance &lt; 30 mL/min ) Severe hepatic dysfunction Severe chronic obstructive pulmonary disease Periprocedural glycoprotein IIb/IIIa inhibitor administration Relevant haematological disease Patient currently , plan , enrol another clinical study involve use investigational drug device within prior 30 day . If female , patient pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>